Since last Q solid numbers the company share price really has been moving, which is good a lot of shareholder value lies to be made in Marksans that being said it’s important to keep an eye on valuation metrics since markets tend to get euphoric at times.
Given the future growth scenario as discussed by management in the recent concall seems to be largely discounted given the current CMP.
The 3000cr mngmt guidance by FY26 seems to be a less optimistic take and might get revised in a couple of quarters. The trailing pe as of writing this stands at 34, bv/cmp at 5.7. Unless we see continued growth in the US OTC market and the promised revival of UK and integration of Europe in the revenue mix the valuation seems reaching a far stretched land.
Disc: invested, holding
| Subscribe To Our Free Newsletter |
